Hospital-acquired infections at an oncological intensive care cancer unit: differences between solid and hematological cancer patients

Patricia Cornejo-Juárez1*, Diana Vilar-Compte1, Alejandro García-Horton1, Marco López-Velázquez1, Silvio Namendys-Silva2 and Patricia Volkow-Fernández1

Abstract

Background: Cancer patients have a higher risk of severe sepsis in comparison with non-cancer patients, with an increased risk for hospital-acquired infections (HAI), particularly with multidrug resistant bacteria (MDRB). The aim of the study is to describe the frequency and characteristics of HAI and MDRB in critically ill cancer patients.

Methods: We conducted an 18-month prospective study in patients admitted ≥48 h to an ICU at a cancer referral center in Mexico. Patients with hematological malignancies (HM) were compared with solid tumors. Demographic and clinical data were recorded. Mortality was evaluated at 30-days.

Results: There were 351 admissions during the study period, among whom 157 (66 %) met the inclusion criteria of the study as follows: 104 patients with solid tumors and 53 with HM. Sixty-four patients (40.7 %) developed 95 episodes of HAI. HAI rate was 4.6/100 patients-days. MDRB were isolated in 38 patients (24 %), with no differences between both groups. Escherichia coli was the main bacteria isolated (n = 24), 78 % were extended spectrum beta-lactamases producers. The only risk factor associated with HAI was the presence of mechanical ventilation for more than 5 days (OR 3.1, 95 % CI 1.6 – 6.2, p = 0.001). At 30-day follow-up, 61 patients (39 %) have died (38 % with solid tumors and 60 % with HM, p < 0.001). No differences were found in mortality at 30-day between patients with HAI (n = 25, 39 %) vs. non-HAI (n = 36, 38.7 %, p = 0.964); neither in those who developed a HAI with MDRB (n = 12, 35.3 %) vs. HAI with non-MDRB (n = 13, 43.3 %, p = 0.51).

Conclusions: Patients with cancer who are admitted to an ICU, have a high risk of HAI, but there were no differences patients with solid or hematologic malignancies.

Keywords: Hospital-acquired infections, Intensive care unit, Multidrug resistance bacteria, Mortality

Background

Critically ill patients in the Intensive care unit (ICU) are at major risk of Hospital-acquired infections (HAI), related with mechanical ventilation, invasive devices, the use of broad-spectrum antibiotics, and parenteral nutrition, among others [1]. Prompt initiation of appropriate antimicrobial therapy is extremely useful in severely ill patients. After results of cultures are obtained, treatment should be re-evaluated to either de-escalate or escalate the antibiotic prescription. This is associated with optimal costs, decreased incidence of superinfection and minimal development of antimicrobial resistance [2].

Furthermore, cancer patients have a 3- to 5-fold greater risk of severe sepsis in comparison with non-cancer patients, with an increased risk for HAI, particularly with multidrug resistant bacteria (MDRB), which are associated with increased therapeutic failure and high mortality rates [3–8]. Patients with neutropenia or hematological
malignancies (HM) appear to be particularly vulnerable to this situation, compared with patients with solid tumors [9].

The aim of this study was to describe the frequency and characteristics of HAI and MDRB in critically ill patients admitted to an ICU at a cancer referral center during an 18-month period, and to compare patients with solid tumors vs. those with HM.

**Methods**

The National Cancer Institute (INCan) in Mexico is a 135-bed referral teaching hospital located in Mexico City for adult patients with cancer, with an average of 170,000 medical visits, 7,500 hospital discharges, and 3,500 major surgical procedures per year. The ICU is a six-bed service that serves both surgical and medical patients. All antimicrobial prescriptions are supervised and adjusted on a regular basis by Infectious Diseases specialists.

We conducted an 18-month prospective study of HAI in patients admitted at the ICU from March 2013 to September 2014. The study was approved by the Instituto Nacional de Cancerología Ethics Review Board (“Comité de Ética en Investigación”- INCAN/CI/410/15). Consent was not obtained but patient information was anonymous and de-identified prior to analysis. All patients hospitalized in the ICU for ≥48 h were included. The following information was recorded: age, sex, comorbidities, hospitalization and antimicrobials in the previous 3 months, treatment with chemotherapy, radiotherapy or immunotherapy, type of cancer (classified as solid or HM), current status of cancer (complete or partial remission, recent diagnosis, relapsed or progression), stage of disease, reason for ICU admission, time from hospital to ICU admission, severity of illness score using Acute Physiology and Chronic Health Evaluation (APACHE II), organ dysfunctions using Sequential Organ Failure Assessment score (SOFA), length of ICU stay, and ICU mortality rate.

Cultures from blood, urine, surgical site, bronchial secretions, and from any other site with clinical suspicion of infection were performed based on the judgment of the treating physician. Bacteria were cultured using standard microbiological methods. Antimicrobial susceptibility testing was performed by means of the BD Automated Phoenix™ (USA) and the Kirby-Bauer disk diffusion technique in case of resistant strains (Clinical Laboratory Standards Institute, CLSI) [10]. The microorganisms isolated and their susceptibility was recorded. The following MDRB were evaluated: Methicillin-resistant *Staphylococcus aureus* (MRSA); Vancomycin-resistant *Enterococcus faecium* (VRE); Extended-spectrum beta-lactamases (ESBL) *Escherichia coli* and *Klebsiella* spp.; *Pseudomonas aeruginosa*, and *Acinetobacter* spp. resistant to third generation cephalosporins and carbapenems. Other Gram-negative bacteria were considered MDR if they were resistant to fluoroquinolones, third generation cephalosporins, and carbapenems [11].

Infections occurring at more than one site in the same patient were reported as separated infection events, unless the same bacterium was isolated concurrently. HAI were defined using Centers for Disease Control and Prevention criteria (CDC, 2014) [12], and were classified as follows: Central Line-associated Bloodstream Infection (CLABSI); Surgical Site Infection (SSI); Ventilator-associated Pneumonia (VAP); abdominal sepsis, and Catheter-associated Urinary Tract Infections (CA-UTI). Number of ventilator-days, number of central venous catheter (CVC) days, and urinary catheter-days were also recorded.

Mortality and the cause related were evaluated on days 7, 30 and 90, after ICU hospitalization.

**Statistical analysis**

The Student *t* test or the Mann–Whitney *U* test were used to compare continuous variables depending on whether they exhibited a normal or non-normal data distribution, respectively, and the Chi-square or the Fisher exact test were used to compare categorical variables. Variables with *P* values <0.5 in the univariate analysis were included in multivariate analysis. A logistic regression analysis was performed for predicting risk for HAI. A cox regression model was performed for survival analysis. Odds ratios (RR) with 95 % Confidence intervals (95 % CI) were calculated. Rates of overall survival were estimated by means of the Kaplan-Meier method and log-rank test. *P* values ≤0.05 were considered statistically significant. Device utilization ratios, site-specific cumulative incidence rates per 100 patients, and site-specific incidence densities per 1,000 days at risk or per 1,000 catheter-days were calculated. Data was analyzed using Epi-Info (ver. 7) and STATA (ver. 12) software.

**Results**

Three hundred fifty-one patients were hospitalized at the ICU during the study period. One hundred fifty-seven (66 %) patients remained at the ICU for ≥48 h and were included in the study as follows: 104 patients with solid tumors (66 %), and 53 with hematological malignancies (34 %). Eighty patients (51 %) were male; mean age was 48 ± 15 years.

Colorectal cancer and liver/biliary tract were the most frequently solid tumors documented. Leukemia (45.3 %) and lymphoma (37 %) were the main HM included. Most of the patients (63.8 %) were in advanced stages of oncological disease stages (III or IV); 27 patients (17.2 %) had metastases.

The most common causes of ICU admission were different between both groups: patients with solid tumors were...
admitted with hypovolemic shock (26.9 %) and respiratory failure (24 %); while patients with HM had respiratory failure (54.7 %) and septic shock (26.4 %). HM patients had received chemotherapy, radiotherapy or had been hospitalized recently with higher frequency compared with solid tumors. Other clinical and demographic characteristics are shown in Table 1.

Sixty-four patients (40.7 %) developed 95 episodes of HAI-ICU infection within a median of 7 days from ICU admission (IQR, 4–12 days). VAP was diagnosed in 34 patients (21.7 %), rate of VAP/1000 ventilator-days was 27.6. CA-UTI was the second HAI diagnosed in 22 patients (14 %), rate of CA-UTI/1000 catheter-days was 9.3. When comparing patients with solid tumors vs. those with HM, there were no differences among patients with HAI, VAP, CA-UTI, mechanical ventilation, or ICU length-of-stay. Only CA-UTI/1000 catheter-days were different, being more frequent in HM patients (p = 0.03). The classification of different HAIs and the infections rates are displayed in Table 2.

During the study period, 910 cultures were taken; 172 (18.9 %) microorganisms were identified, including 102 Gram negative (59.3 %), 46 Gram positive (26.7 %), and 24 yeasts (14 %). MDRB were identified in 35 patients (24.2 %), with no differences between both groups (p = 0.94). *Escherichia coli* was the most frequent bacterium isolated (78 % were ESBL producers). Other bacteria are shown in Fig. 1.

Regarding fungi, there were seven candidemia episodes (three due to *Candida glabrata*, two due to *C. tropicalis*, one due to *C. parapsilosis*, and one due to *C. albicans*). Three candidemia episodes were associated with severe neutropenia, two with CVC infection, and two with parenteral nutrition. Six of these patients died (86 %), in a mean time of eight days since *Candida* growth. *Aspergillus* spp. was identified in broncho-alveolar samples, three patients (two *A. fumigatus* and one *A. flavus*), all with hematologic malignancies, severe neutropenia and lung nodules in scan tomography. Two patients with *Aspergillus* died.

Concomitant infections were documented in 19 patients; two different bacteria were documented in 15 patients (three with abdominal sepsis, eight with pneumonia and four with SSI), one patient had influenza virus with a bacterial co-infection, one patient with CLABSI had a Candida plus a bacteria, and two patients with SSI had two different bacteria plus Candida.

In the logistic regression model, over five days of mechanical ventilation was the only statistically significant factor for HAI (OR 3.12, 95 % CI 1.6 – 6.2, p = 0.001).

30-days overall mortality was 61 patients (39 %): 29 (28 %) with solid tumors and 32 (60.3 %) with HM (p < 0.001).

Sixty-one patients died at 30-day follow-up, no differences were found between patients with HAI (n = 25, 39 %) vs. non-HAI (n = 36, 38.7 %, 0.964); neither at 90-day follow-up (n = 27, 42.2 % vs. n = 52, 55.9 %, respectively, p = 0.09). No differences were found in mortality at 30-day between patients who developed a HAI with MDRB (n = 12, 35.3 %) vs. HAI with non-MDRB (n = 13, 43.3 %, p = 0.51) Fig. 2.

**Discussion**

In oncological patients, the interaction of multiple factors related to immune suppression, skin or mucosal disruption, extensive antibiotic use, complex surgical procedures and the presence of invasive devices, augment the risk of HAIs, leading to an increase in the length of hospital stay, morbidity and mortality [13].

As a result, the number of patients admitted to the ICU, either for cancer-related complications or for treatment-associated side effects is steadily increasing [9].

Although we did not specify the chemotherapy regimens, it is important to consider that hematologic patients, particularly with acute leukaemias, aggressive regimens amplify disease-induced immunosuppression and result in severe and long lasting neutropenias which could favour the development of severe infections. This was not confirmed in this study, most likely because of the low number of patients with this disease.

Some studies describe as the main reasons to the ICU admission, septic shock, respiratory failure and hypovolemic shock secondary to extensive surgical resection in patients with solid tumors. In this study we found differences for ICU admission in both groups: in patients with HM the most frequent cause was respiratory failure (54.7 %), it was related to several causes such as pneumonia, acute respiratory distress syndrome, diffuse alveolar hemorrhage and pulmonary embolisms. However, in patients with solid tumors the main reason for ICU admission was hypovolemic shock secondary to schedule or emergency surgical resection (29.9 %). This percentage was higher than the one reported in other study performed in the same ICU (31.6 % for septic and hypovolemic shock) [14]. Reports from other parts of the world not even include hypovolemic shock within the first causes of admission to ICU [15–17]. One possible explanation for the high percentage we found, is that patients admitted to our hospital have advanced cancer stages, with tumor adhesion to adjacent organs, therefore require extensive surgeries, with multiple organ resection, which increases bleeds and surgical morbidity.

HAI prevalence varies among hospitals and among countries. There has been reported an increase in patients with cancer during the last decade [18]. Some studies have reported a wide variation rate between 5.3 and 56.1 % [19]. Our HAI rate was 40.7 %. The most frequent infection was VAP (26.7 %, 28.4/1,000 ventilator-days). The VAP rate was similar to the ones described in other ICUs in developing
| Characteristic – n (%) | Total (N = 157) | Solid tumor (n = 104) | Hematological malignancies (n = 53) | P-value |
|------------------------|-----------------|----------------------|------------------------------------|---------|
| Gender – Masculine     | 80 (51)         | 43 (41.3)            | 37 (69.8)                          | <0.001  |
| Age (years)            | 48 ± 15         | 50.5 ± 15.5          | 43.9 ± 15.7                        | 0.009   |
| Comorbidities          |                 |                      |                                    | 0.257   |
| Arterial hypertension  | 31 (19.7)       | 23 (22.1)            | 8 (15.1)                           |         |
| Diabetes mellitus      | 29 (18.5)       | 23 (22.1)            | 6 (11.3)                           |         |
| Smoking                | 19 (12.1)       | 13 (12.5)            | 6 (11.3)                           |         |
| Obesity                | 19 (12.1)       | 15 (15.4)            | 4 (7.5)                            |         |
| HIV                    | 2 (1.3)         | 1 (1)                | 3 (5.7)                            |         |
| Other                  | 13 (8.3)        | 8 (7.7)              | 5 (9.4)                            |         |
| Type of tumor          |                 |                      |                                    |         |
| NHL                    | 22 (14)         | -                    | 22 (41.5)                          |         |
| HL                     | 2 (1.3)         | -                    | 2 (3.8)                            |         |
| Acute leukemia         | 22 (14)         | -                    | 22 (41.5)                          |         |
| Myeloma multiple       | 4 (2.5)         | -                    | 4 (7.5)                            |         |
| Myelodysplastic        | 4 (2.5)         | 12 (11.5)            | 4 (7.5)                            |         |
| Germ cell tumors       | 12 (7.6)        | 23 (22.1)            | -                                  |         |
| Gastrointestinal       | 23 (14.6)       | 10 (9.6)             | -                                  |         |
| Cervical               | 10 (6.4)        | 10 (9.6)             | -                                  |         |
| Breast                 | 10 (6.4)        | 10 (9.6)             | -                                  |         |
| Skin and soft tissue   | 10 (6.4)        | 8 (7.7)              | -                                  |         |
| Ovarian                | 8 (5.1)         | 7 (6.7)              | -                                  |         |
| Head and neck          | 7 (4.5)         | 20 (19.2)            | -                                  |         |
| Other tumors           | 20 (12.7)       |                      |                                    |         |
| Stage                  |                 |                      |                                    |         |
| I-II                   | 38 (36.2)       | 33 (86.8)            | 50 (74.6)                          | 0.211   |
| III-IV                 | 67 (63.8)       | 5 (13.2)             | 17 (25.4)                          |         |
| Oncologic status       |                 |                      |                                    | 0.03    |
| Recent diagnosis       | 96 (61.1)       | 57 (54.8)            | 39 (73.6)                          |         |
| Progression            | 30 (19.1)       | 21 (20.2)            | 9 (17)                             |         |
| Relapse                | 19 (12.1)       | 14 (13.5)            | 5 (9.4)                            |         |
| Complete remission     | 12 (7.6)        | 12 (11.5)            | 0                                  |         |
| Chemotherapy in the last 30 days | 48 (30.6) | 19 (18.3) | 29 (54.7) | <0.001 |
| Radiotherapy in the last 6 months | 11 (7)   | 3 (2.9)   | 8 (15.1)   | 0.007  |
| Neutropenia            | 9 (5.7)         | 4 (3.8)              | 5 (9.4)                            | 0.02    |
| Pancytopenia           | 20 (12.7)       | 1 (1)                | 19 (35.8)                          | <0.001  |
| Hospitalization in the last 90 days | 45 (28.7) | 21 (20.2) | 24 (45.3) | 0.001  |
| ICU admission          |                 |                      |                                    | <0.001  |
| Respiratory failure    | 54 (34.4)       | 25 (24)              | 29 (54.7)                          |         |
| Septic shock           | 34 (21.7)       | 20 (19.2)            | 14 (26.4)                          |         |
| Hypovolemic shock | 29 (18.5) | 28 (26.9) | 1 (1.9) |
|-------------------|-----------|-----------|---------|
| Post-surgical     | 13 (8.3)  | 13 (12.6) | 0       |
| Post-CPR          | 7 (4.4)   | 6 (5.8)   | 1 (1.9) |
| Other causes\(^b\)| 20 (12.7) | 12 (11.5) | 8 (15.1)|
| Days from hospitalization to ICU admission\(^i\) | 2 (1.8) | 0 (1.7) | 4 (1.13) | 0.02 |
| APACHE-II score\(^h\) | 18.9 ± 6.4 | 18.4 ± 6.7 | 19.9 ± 5.6 | 0.134 |
| SOFA score\(^k\) | 8.6 ± 3.6 | 8.4 ± 3.9 | 9.2 ± 3.1 | 0.197 |

\(^{a}\)Mean ± standard deviation
\(^{b}\)HIV human immunodeficiency virus; other comorbidities: 4 patients with thyroid dysfunction, 1 with chronic kidney failure, 2 with chronic liver failure, 1 with Down syndrome, 1 with ischemic heart disease, 3 with neurologic disease and 1 with rheumatologic disease
\(^{c}\)NHL non-Hodgkin lymphoma; HL = Hodgkin lymphoma; other tumors: lung, bladder, kidney, peripheral nerve, brain
\(^{d}\)One patient who received hematopoietic stem cell transplantation
\(^{e}\)Stage was documented in 105 patients: 38 solid and 67 hematologic, percentage was calculated with these numbers. The rest of the patients were not stratified because had a neoplasia unclassifiable
\(^{f}\)One patient received sorafenib for kidney cancer and one received bortezomib for multiple myeloma. Three patients received radiotherapy with concomitant chemotherapy
\(^{g}\)Four patients had anemia plus neutropenia, and five had neutropenia plus thrombocytopenia
\(^{h}\)Kidney failure, cerebrovascular accident, water-electrolyte imbalance, metabolic acidosis and neurologic impairment
\(^{i}\)Median (interquartile range)
\(^{j}\)Acute Physiology and Chronic Health Evaluation
\(^{k}\)Sequential Organ Failure Assessment
More than five days of mechanical ventilation was the only risk factor associated to HAI in multivariate analysis (OR 3.12, CI 95% 1.6–6.2, p = 0.001), as has been reported previously [21].

Surgical site infection (SSI) was the second HAI documented: 72 surgeries were performed during the study period; the infection rate was 16.7 (the SSI infection rate reported during 2013 in our institution was 9.9). It is relevant to highlight that 28% of the surgeries were emergency procedures, and the majority of these comprised complicated and extensive interventions.

In various reports, CA-UTIs are described as the most common nosocomial infection (around 40%) [22]. These infections do not cause severe mortality or morbidity, but can progress into severe infections such as secondary bacteremia or septic shock, in addition to significantly

### Table 2: Hospital-acquired infections (HAI) at the Intensive Care Unit

| Characteristic | Total (n = 157) | Solid tumor (n = 104) | Hematological malignancies (n = 53) | P-value |
|---------------|----------------|----------------------|-----------------------------------|---------|
| HAI episodes  | 64 (40.7)      | 42 (40.4)            | 22 (41.2)                         | 0.895   |
| MDRB-HAIa     | 38 (24.2)      | 23 (22.1)            | 12 (22.6)                         | 0.94    |
| Days of ICU stayb | 6 (4.11)     | 6 (4.10)             | 6 (5.11)                          | 0.368   |
| Incidence rate per 100 patient-days | 4.6 | 4.6 | 4.7 | 0.952 |

Type of HAI:
- **VAP**
- **VAP/1,000 ventilator-days**
- **CA-UTI**
- **CA-UTI/1,000 catheter-days**
- **CLABSI**
- **CLABSI/1,000 catheter-days**
- **SSI**
- **Abdominal sepsis**

| Characteristic | Total (n = 157) | Solid tumor (n = 104) | Hematological malignancies (n = 53) | P-value |
|---------------|----------------|----------------------|-----------------------------------|---------|
| HAI episodes  | 64 (40.7)      | 42 (40.4)            | 22 (41.2)                         | 0.895   |
| MDRB-HAIa     | 38 (24.2)      | 23 (22.1)            | 12 (22.6)                         | 0.94    |
| Days of ICU stayb | 6 (4.11)     | 6 (4.10)             | 6 (5.11)                          | 0.368   |
| Incidence rate per 100 patient-days | 4.6 | 4.6 | 4.7 | 0.952 |

### Notes:
- MDRB: multidrug-resistant bacteria (ESBL- *Escherichia coli*; Multidrug-resistant-extensively drug-resistant (MDR/XDR): *Pseudomonas aeruginosa; MDR- Acinetobacter baumannii; Methicillin-resistant *Staphylococcus aureus, Vancomycin-resistant enterococcus)
- Median Interquartile (IQ) range
- VAP: ventilator associated pneumonia, CA-UTI: catheter related urinary tract infection, CLABSI: central line associated bloodstream infection, SSI: surgical site infection
- 131 patients required mechanical ventilation
- Surgery was performed in 72 patients

In various reports, CA-UTIs are described as the most common nosocomial infection (around 40%) [22]. These infections do not cause severe mortality or morbidity, but can progress into severe infections such as secondary bacteremia or septic shock, in addition to significantly

**Fig. 1** Main bacteria isolated in patients with Hospital-Acquired Infection at the Intensive Care Unit (HAI-ICU), divided into susceptible and multidrug-resistant bacteria (MDRB). The percentage was obtained from the total number of microbiological isolates (n = 172)
increasing the hospital costs [23]. We found CA-UTI as the third HAI in the ICU (13.4 %, 8.9 infections/1,000 catheter-days), as the same as reported by other authors [20]. Median of indwelling urinary catheter stay were 16 days in patients with CA-UTI compared with 10 days in non-CA-UTI patients.

The CLABSI rate was 2.5 % (1 infection/1,000 catheter-days). In some U.S. studies, which report prevalence, the range varies from 1.8 to 7.6/1,000 catheter-days [24]. In one research conducted in eight developing countries, the rate varied between 4.2 and 14.4/1,000 catheter-days [17]. The low rate found in this series is attributed to strict standardized protocol of care provided by an intravenous therapy team nurses working for over two decades [25, 26].

E. coli was the most frequent pathogen isolated, 78 % were ESBL producers. This percentage is considerably higher than reported elsewhere in our country (range between 33 and 51 %) [27–29], but it is important to note that these studies included patients hospitalized in different wards, not only from ICU where the prevalence of MDRB is usually higher.

In recent years, widespread MDRB in hospitals had complicated the medical care and infection prevention measures. MDRB pathogens are associated with worse outcomes related with inferior therapeutic options and delay in initiation of appropriate therapy, and probably with increased virulence of these strains [30]. In this study we found 24.2 % of MDRB, which is lower when compared to a retrospective study performed from 2007 to 2011 in the same ICU, when the HAI rate was 39.7 % [31]. In another Mexican study with patients admitted in ICU, the incidence of MDRB was 64.5 % [32].

In this report, overall 30-day mortality was 39 % with ranges between 28 % in patients with solid tumors until 60.4 % in HM group. The poor prognosis of patients with HM, especially those who received hematopoietic stem cell transplantation (HSCT), has been well documented [17]. We did not have HSCT patients because they are treated exclusively in the transplant unit. We found a difference in mortality related with the cause of admission to ICU: 60 % in patients admitted with respiratory failure, 29.4 % in patients with septic shock and 10.3 % in scheduled surgical patients, but this could be related with the oncology disease, because HM patients had also more frequently respiratory failure. In another study, that included oncology patients admitted at the ICU, the overall hospital mortality was 30 %, (range, 10 % to 70 %) [9, 17].

Early management of organ dysfunction is crucial in the treatment of critically ill patients; late ICU admission has been associated with greater mortality [9]. We found a significant delay in ICU admission in patients with HM (median 2 days compared solid tumors median 0 days), which could be also related with higher mortality in these patients.

Infection control measures are strict in our ICU: at admission, two blood cultures, urine, respiratory secretions and other cultures are required; broad-spectrum antibiotics are initiated as soon as patient arrival. An antimicrobial re-evaluation is made in the first 48–72 h when cultures results are available and according to clinical evolution to either de-escalate or escalate the antibiotic prescription; antibiotics schemes are discussed and reviewed periodically with all staff (intensive care, infectious disease and medical or surgical oncologists physicians); the duration of antimicrobials treatment are shortened as much as possible; surveillance hand hygiene program, and follow antibiotic prophylaxis guides [2].

Some limitations of this study are that the results correspond to a single-center and did not obtain data related to the long-term survival. However, we believe these results provide insight into the prevalence of HAI, particularly MDRB at a cancer referral center, and can be extrapolate results to other hospitals with similar characteristics.

**Conclusions**

Our study indicates that the prevalence of HAI is similar than other reports performed in cancer patients. There were no differences between patients with HAI vs. non-HAI, neither in those who had a MDRB isolated. Adherence to the guidelines for the prevention and control of infections are the most useful tool to decrease HAI infections and improve outcomes in susceptible patients.

**Abbreviations**

APACHE II, Acute Physiology and Chronic Health Evaluation II; CA-UTI, Catheter-associated urinary tract infections; CLABSI, Central line-associated bloodstream infection; CVC, Central venous catheter; ESBL, Extended-spectrum beta-lactamases; HAI, Hospital-acquired infections; HCT, Hematological stem cell transplantation; ICU, Intensive care unit; MDRB,
Multidrug resistance bacteria; SOFA, Sequential Organ Failure Assessment; SSI, Surgical site infection; VAP, Ventilator associated pneumonia

Acknowledgments
We thank the Microbiology Laboratory personnel who are responsible for processing all culture specimens at INCan, Mexico City.

Funding
This study had no funding.

Availability of data and materials
Data were obtained from medical records and microbiology laboratory. Both are available permanently.

Authors’ contributions
PCJ Conception, design and wrote the manuscript. AGH, MLV Acquisition of data. SÑS, DVC, PVF Interpretation of data and revising manuscript for important intellectual content. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Ethics approval and consent to participate
The study was approved by the Instituto Nacional de Cancerología Ethics Review Board (“Comité de Ética en Investigación”- INCan/CII/140/15). Consent was not obtained but patient information was anonymous and de-identified prior to analysis.

Author details
1Infectious Diseases Department, Instituto Nacional de Cancerología, Av. San Fernando No. 22, Col. Sección XVI, Tlalpan, 14000 México, D.F., Mexico.
2Department of Critical Care Medicine, Instituto Nacional de Cancerología, Av. San Fernando No. 22, Col. Sección XVI, Tlalpan, 14000 México, D.F., Mexico.

Received: 24 October 2015 Accepted: 25 May 2016

Published online: 10 June 2016

References
1. Vitrat V, Hautefeuille S, Janssen C, Bouson D, Sirotot M, Pagani L. Optimizing antimicrobial therapy in critically ill patients. Infect Drug Resist. 2014;7:261–71.
2. Textoris J, Wilarius S, Martin C, Leone M. Overview of antimicrobial therapy in intensive care units. Expert Rev Ant Infect Ther. 2011;9:97–109.
3. Weinstein RA. Nosocomial infection update. Emerg Infect Dis. 1998;4:416–20.
4. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. EPIC II Group of Investigators International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302:2323–9.
5. Ayl NY, Al-Mousa HH, Al Asar SM. Nosocomial infections in a medical-surgical intensive care unit. Med Princ Pract. 2008;17:373–7.
6. Montassier E, Batard E, Gassinne T, Pothel G, de la Cochetière MF. Recent changes in bacteraemia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. Eur J Clin Microbiol Infect Dis. 2013;32:491–50.
7. Neidell NJ, Cohen B, Furuya Y, Hill J, Leon CY, Gled S, et al. Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible pathogens. Clin Infect Dis. 2012;55:807–15.
8. Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. Ann Intern Med. 2011;154:298–314.
9. Kostakou E, Rovina N, Kyriakopoulou M, Koulouris NG, Koutsoukou A. Critically ill cancer patient in intensive care unit: issues that arise. J Crit Care. 2014;29:817–22.
10. Clinical and Laboratory Standards Institute (CLSI): Performance standards for antimicrobial susceptibility testing. Approved Standard M100-S23. Wayne, PA: Clinical and Laboratory Standards Institute; 2013.
11. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CE, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–81.
12. CDC/NHSN Surveillance Definition of Healthcare-Associated Infection and Criteria for Specific Types of Infections in the Acute Care Setting. January 2015. www.cdc.gov/nhsn/PDFs/ppticManual/17/17psNosInfrDef_current.pdf. Accessed 15 Feb 2013.
13. Ariza-Heredia EJ, Chernsly RF. Infection control practices in patients with hematological malignancies and multidrug-resistant organisms: special considerations and challenges. CI Lymph Myelom Leuk. 2014;14(Suppl):90–10.
14. Namendys-Silva SA, Texcocano-Becerril J, Herrera-Gómez A. Prognostic factors in critically ill patients with solid tumours admitted to an oncological intensive care unit. Anaesth Intensive Care. 2010;38:317–24.
15. Unseld S, Schuepbach RA, Maggiorini M. ICU, hospital and one year mortality of patients suffering from solid or haematological malignancies. Swiss Med Wkly. 2013;143:w13741. doi:10.4414/smw.2013.13741.
16. Song JU, Suh GY, Chung MP, Kim H, Kwon OJ, Jung CW, Kang WK, Park K, Jeon K. Risk factors to predict outcome in critically ill cancer patients receiving chemotherapy in the intensive care unit. Support Care Cancer. 2011;19:491–5.
17. Aygencel G, Turkuoglu M, Turkuoz Sukac G, Benelli M. Prognostic factors in critically ill cancer patients admitted to the intensive care unit. J Crit Care. 2012;26:18–26.
18. Sammon J, Trinh VQ, Ravi P, Sukumar S, Genvais MK, Shariat SF, et al. Health care-associated infections after major cancer surgery: temporal trends, patterns of care, and effect on mortality. Cancer. 2013;119:2317–24.
19. Dereli N, Ozayar E, Dereli M, Sahin S, Koc F. Three-year evaluation of nosocomial infection rates of the ICU. Rev Bras Enferm. 2013;63:73–84.
20. Rosenthal VD, Maki DG, Salomao R, Moreno CA, Mehta Y, Higuera F, et al. Device-associated nosocomial infections in SS intensive care units of 8 developing countries. Ann Intern Med. 2006;145:582–91.
21. Coffin SE, Komplas M, Classen D, Arias KM, Podgorny K, Anderson DJ, et al. Strategies to prevent ventilator-associated pneumonia in acute care hospitals. Infect Control Hosp Epidemiol. 2008;29 Suppl 3:31–40.
22. HIdron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, et al. National Healthcare Safety Network Team; Participating National Healthcare Safety Networks. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infect Control Hosp Epidemiol. 2008;29:996–1011.
23. Wagenlehner FM, Weidner W, Naber KG. Emergence of antibiotic resistance amongst hospital-acquired urinary tract infections and pharmacokinetic/pharmacodynamics considerations. J Hosp Infect. 2005;60:191–200.
24. DiGiorgio MJ, Fatica C, Oden M, Bolwell B, Sekeres M, Kalaycio M, et al. Development of a modified surveillance definition of central line-associated bloodstream infections for patients with hematologic malignancies. Infect Control Hosp Epidemiol. 2012;33:865–8.
25. Volkow P, Sanchez-Mejorada G, de la Vega SL, Vazquez C, Tellez O, Baez RM, et al. Experience of an intravenous therapy team at the Instituto Nacional de Cancerologia (Mexico) with a long-lasting, low-cost silastic venous catheter. Clin Infect Dis. 1994;18:719–25.
26. Volkow P, Vazquez C, Tellez O, Aguilar C, Barrera L, Rodriguez E, et al. Polyurethane II catheter as long-indwelling intravenous catheter in patients with cancer. Am J Infect Control. 2003;31:392–6.
27. Morfin-Otero R, Noriega BR, Dowzicky MJ. Antimicrobial susceptibility trends among gram-positive and -negative clinical isolates collected between 2005 and 2012 in Mexico: results from the Tigecycline Evaluation and Surveillance Trial. Ann Clin Microbiol Antimicrob. 2015;14:53.doi:10.1186/s12941-015-0116-y.
28. Gales AC, Castanheira M, Jones RN, Sader HS. Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008–2010). Diagn Microbiol Infect Dis. 2012;72:364–60.
29. Morfin-Otero R, Tinoco-Favila JC, Sader HS, Caulin-Gutierrez L, Perez-Gomez HR, Gonzalez-Diaz E, Petersen L, Rodriguez-Noriega E. Resistance trends in gram-negative bacteria: surveillance results from two Mexican hospitals, 2005–2010. BMC Res Notes. 2012;5:277.doi:10.1186/1756-0500-5-277.
30. Schwebke MJ, Carmeli Y. The effect of antimicrobial resistance on patient outcomes: importance of proper evaluation of appropriate therapy. Curr Opin Infect Dis. 2009; doi:10.1097/QCO.0b013e32831741e6.
31. Cornejo-Juárez P, Vilar-Compte D, Pérez-Jiménez C, Namendys-Silva SA, Sandoval-Hernández S, Volkov-Fernández P. The impact of hospital-acquired infections with multidrug-resistant bacteria in an oncology intensive care unit. Int J Infect Dis. 2015;31:31–4.